Apyx Medical Corp. (APYX) intrinsic value & 10-year financials

Apyx Medical Corp. (APYX) has a Graham intrinsic value of $26.99 per share. At $2.55 on Oct 17, 2026, the stock trades 91% below that value. Over the last 10 fiscal years revenue grew 4.2% a year to $52.8M, with an average return on invested capital of -54.1%.

Graham intrinsic value
$26.99
Share price (Oct 17, 2026)
$2.55
Price vs Graham value
91% below
Market cap
$88.3M
Revenue (FY2025)
$52.8M
Revenue growth (10-yr CAGR)
4.2%
ROIC (10-yr avg)
-54.1%
Free cash flow (FY2025)
-$9.1M

APYX 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $52.8M -$11.2M — -$9.1M -12.2% -30.3%
FY2024 $48.1M -$23.5M — -$18.8M -39.2% -89.6%
FY2023 $52.3M -$18.7M -$0.54 -$5.8M -33.0% -62.2%
FY2022 $44.5M -$23.2M -$0.67 -$21.3M -52.9% -92.8%
FY2021 $48.5M -$15.2M -$0.44 -$11.2M -29.8% -64.3%
FY2020 $27.7M -$11.9M -$0.35 -$16.6M -72.5% -69.9%
FY2019 $28.2M -$19.7M -$0.58 -$19.8M -73.9% -49.1%
FY2018 $16.6M -$9.5M $1.86 -$21.4M -81.9% -22.6%
FY2017 $10.2M -$5.1M -$0.17 -$4.3M -51.4% -34.7%
FY2016 $36.6M -$4.0M -$0.15 -$3.1M -10.4% -25.8%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Apyx Medical Corp has demonstrated mature, steady growth, with revenue compounding at 4.2% annually over the past decade.

Apyx Medical Corp has historically struggled to out-earn its cost of capital, averaging just -54.1% ROIC.

Over the decade, Apyx Medical Corp shows that the company has leveraged its balance sheet to sustain operations.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Apyx Medical Corp is modeled at 4.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $26.99 per share.

APYX stock: frequently asked questions

What is the intrinsic value of Apyx Medical Corp. (APYX) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 4.2% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, APYX's intrinsic value is about $26.99 per share.

Is APYX stock undervalued?

At $2.55 (close on Oct 17, 2026), APYX trades 91% below its Graham value of $26.99. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Apyx Medical Corp. grown?

Revenue went from $36.6M in fiscal 2016 to $52.8M in fiscal 2025, a compound annual growth rate of 4.2%. Net income was -$11.2M in fiscal 2025.

Does Apyx Medical Corp. generate free cash flow?

Apyx Medical Corp. generated -$9.1M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 0 of the last 10 reported years.

What is APYX's return on invested capital?

Average ROIC over the last 10 fiscal years was -54.1%, and average return on equity was -42.3%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this APYX data come from?

From Apyx Medical Corp.'s annual 10-K filings on SEC EDGAR, most recently filed Aug 6, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar surgical & medical instruments & apparatus stocks